A recent prospective multicenter trial presented at the World Conference on Lung Cancer evaluated pembrolizumab and chemotherapy in the setting of recurrent EGFR/ALK-positive NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.